KRAS Recombine F Sequence:GTC TT and 1 more item

The University of Nebraska Medical Center, a state agency operating under Nebraska's Board of Regents, awarded a purchase order valued at $11.97 to Integrated DNA Technologies Inc., located in Chicago, Illinois, on February 24, 2026. The contract covers the delivery of two synthetic DNA oligonucleotide products: KRAS Recombine F (sequence GTC TT) priced at $5.70 per unit and KRAS Recombine R (sequence CTC TT) priced at $6.27 per unit, with one unit ordered for each line item. Performance is scheduled for completion by March 3, 2026, with delivery to the University of Nebraska Medical Center's Shipping and Receiving department in Omaha, Nebraska.

The purchase order is structured as a standard procurement transaction governed by the University of Nebraska's Standard Terms of Purchase, with payment terms of Net 30 and freight prepaid on a Free on Board destination basis. The contract represents a routine materials acquisition for what appears to be molecular biology or genetic research applications at the Medical Center. As a tax-exempt state educational institution, the University of Nebraska Medical Center processed this acquisition under its acquisition authority without applicable sales tax considerations.